臨床婦人科産科70巻11号

2016年11月発行

今月の臨床 骨粗鬆症の最新トピックス─ガイドラインの大幅改訂を迎えて

治療

副甲状腺ホルモン薬

著者： 倉林工¹

所属機関： ¹新潟市民病院産婦人科

ページ範囲：P.1050 - P.1056

文献概要

●副甲状腺ホルモン薬のテリパラチドは現在使用可能な唯一の骨形成促進薬である．

●テリパラチドには，連日製剤と週1回投与で骨代謝作用が若干異なること，投与期間に縛りがあること，薬価が高いことなどの特徴がある．

●著しい骨密度低下例，重度あるいは複数の椎体骨折を有する例，大腿骨近位部骨折の既往例など骨折リスクの高い重症骨粗鬆症患者が良い適応となる．

●今後は投与中止後の骨吸収抑制薬との逐次療法など，効果的な投与方法が期待される．

参考文献

1）一居　充，他 : PTHの骨カルシウム代謝調節作用．ファーマナビゲーター PTH編（松本俊夫 編）．pp38─45，メディカルレビュー社，2013

2）Mosekilde L : Primary hyperparathyroidism and the skeleton. Clin Endocrinol（Oxf） 69 : 1─19, 2008

3）Dempster DW,et al : Anabolic actions of parathyroid hormone on bone. Endocr Rev 14 : 690─709, 1993

4）Miyauchi A, et al : Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study : 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47 : 493─502, 2010

5）Rubin MR, et al : New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32 : 285─307, 2003

6）Nakamura T, et al : Randomized Teriparatide［human parathyroid hormone（PTH） 1-34］Once-Weekly Efficacy Research（TOWER） trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97 : 3097─3106, 2012

7）Sugimoto T, et al : Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int 25 : 1173─1180, 2014

8）骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン2015年版．ライフサイエンス出版，2015

9）Neer RM, et al : Effect of parathyroid hormone（1-34）on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 : 1434─1441, 2001

10）Tsai JN, et al : Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength（DATA-HRpQCT study）. J Clin Endocrinol Metab 101 : 2023─2030, 2016

11）Zanchetta JR, et al : Effects of teriparatide［recombinant human parathyroid hormone（1-34）］on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18 : 539─543, 2003

12）Gallagher JC, et al : Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90 : 1583─1587, 2005

13）Nakano T, et al : Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks : subgroup analysis of the Teriparatide Once-Weekly Efficacy Research（TOWER） trial. J Bone Miner Metab 32 : 441─446, 2014

14）Ito M, et al : The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporos Int 25 : 1163─1172, 2014

15）Sone T, et al : The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk. Bone 64 : 75─81, 2014

16）Andrews EB, et al : The US postmarketing surveillance study of adult osteosarcoma and teriparatide : study design and findings from the first 7 years. J Bone Miner Res 27 : 2429─2437, 2012

17）Obermayer-Pietsch BM, et al : Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23 : 1591─1600, 2008

18）Nevitt MC, et al : Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment : a meta-analysis. Osteoporos Int 17 : 1630─1637, 2006

19）Kaufman JM, et al : Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis : treatment and discontinuation of therapy. Osteoporos Int 16 : 510─516, 2005

20）Leder BZ, et al : Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100 : 697─706, 2015

21）Kurland ES, et al : The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide［human parathyroid hormone（1-34）］. Osteoporos Int 15 : 992─997, 2004

22）Sugimoto T, et al : Vertebral fracture risk after once-weekly teriparatide injections : follow-up study of Teriparatide Once-Weekly Efficacy Research（TOWER） trial. Curr Med Res Opin 29 : 195─203, 2013

23）Eastell R, et al : Sequential treatment of severe postmenopausal osteoporosis after teriparatide : final results of the randomized, controlled European Study of Forsteo（EUROFORS）. J Bone Miner Res 24 : 726─736, 2009